Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 [Yahoo! Finance]

Lyell Immunopharma, Inc.  (LYEL) 
PDF On track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024 IND for second [Read more]